Non Invasive Preimplantation Genetic Testing Nipgt A

The Non-invasive Pre-implantation genetic testing, also called NiPGT is an upcoming, innovative and promising technology that does not require a foetal biopsy and facilitates access to the control of chromosomal abnormalities in the embryo during an IVF cycle.

Overview

Non-invasive Preimplantation Genetic testing, also called niPGT is an upcoming, innovative and promising technology that does not require a foetal biopsy and facilitates access to the control of chromosomal abnormalities in the embryo during the ART cycle.

In the early days of PGT-A, the challenge of science was to be able to control the genetic makeup of embryos without having to biopsy their cells. In recent years, research in this area has intensified and several genetics laboratories have already developed platforms for the analysis of chromosomal abnormalities at the blastocyst stage from alternative sources of their cellular DNA. This is a genetic analysis carried out on the free DNA contained in the culture material where the embryos develop as part of ART.

It helps in improving the ART outcomes in patients with advanced age, recurrent miscarriages, recurrent IVF failures and patients with genetic disorders. Hence, this technique should definitely be offered to these categories of patients in order to improve their success rate.

It has been observed that as many as 50% of grade 1 embryos might not be genetically normal in a couple adopting pregnancy at an advance age. Thus, when these embryos are selected according to their chromosomal robustness, the outcome of the ART process improves, leading to a healthy pregnancy. Also, the patient will be able to go for a single embryo transfer without compromising the success and hence, the burden of multiple pregnancies and the complications associated with it reduces.

This procedure is expected to become a reality in the near future. If so, the niPGT would be non-invasive, precise and inexpensive.